1. Home
  2. HSLV vs WVE Comparison

HSLV vs WVE Comparison

Compare HSLV & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Highlander Silver Corp. Common Shares

HSLV

Highlander Silver Corp. Common Shares

N/A

Current Price

$5.17

Market Cap

893.0M

Sector

N/A

ML Signal

N/A

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$5.20

Market Cap

994.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HSLV
WVE
Founded
N/A
2012
Country
Canada
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
893.0M
994.1M
IPO Year
2024
2015

Fundamental Metrics

Financial Performance
Metric
HSLV
WVE
Price
$5.17
$5.20
Analyst Decision
Strong Buy
Analyst Count
0
16
Target Price
N/A
$29.81
AVG Volume (30 Days)
361.3K
2.6M
Earning Date
05-28-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,704,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$37.60
$85.67
P/E Ratio
N/A
N/A
Revenue Growth
N/A
149.43
52 Week Low
$3.88
$5.01
52 Week High
$6.77
$21.73

Technical Indicators

Market Signals
Indicator
HSLV
WVE
Relative Strength Index (RSI) 58.64 37.53
Support Level $5.08 N/A
Resistance Level $5.28 $6.39
Average True Range (ATR) 0.23 0.35
MACD 0.11 -0.06
Stochastic Oscillator 72.73 15.71

Price Performance

Historical Comparison
HSLV
WVE

About HSLV Highlander Silver Corp. Common Shares

Highlander Silver Corp. is a mineral exploration company engaged in the acquisition, exploration and evaluation of mineral properties located in Peru. It is focused on advancing the bonanza grade San Luis gold-silver project that is located in Central Peru. The company has determined that it has one operating segment, being the exploration of mineral properties.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: